Newsletter Sign-Up

XDNA

Strategic CRISPR & Gene Editing Technology Index

Why Exposure to this Index

Strategic CRISPR & Gene Editing Technology Index measures the performance of companies that specialize in DNA modification systems, and technologies, for a variety of applications including basic biological research, development of biotechnological products, and treatment of diseases as well as next-generation sequencing that may be used at various stages of a genome editing workflow.

INDEX DETAILS

Index Name
Strategic CRISPR & Gene Editing Technology Index
Index Calculator
Morgate Benchmarks Ltd
Weighting Method
Modified Market Cap
Rebalance
Quarterly
Weighted Avg Market Cap
-

Documents

Index Fact Sheet
Download
Index Methodology
Download

Index Overview

The Strategic CRISPR & Gene Editing Technology Index seeks to provide total return by investing in a passively managed, concentrated portfolio of companies that engage in CRISPR & gene editing technology activities.

  • Designed to capitalize on the burgeoning megatrends that are disrupting the genomic and life science industries.
  • Targets companies in the US and developed markets that operate across three CRISPR & Gene Editing sub-sectors, including:
    • CRISPR & Gene Editing Technology sub-sector: Includes companies that specialize in DNA modification systems, and technologies, for a variety of applications including basic biological research, development of biotechnological products, and for the treatment of diseases. CRISPR & gene editing technology enables genetic elements to be mutated, silenced, induced ore replaced. The most common use of DNA modification technology is the targeting of cells within the body to treat genetic disease.
    • Gene Editing Development Solutions sub-sector: Includes companies that have deep scientific, technical and clinical development experience, potentially along with an intellectual property portfolio, that have rights to develop CRISPR or gene-editing based therapeutic products or targets and/or jointly develop potential products with CRISPR & gene editing technology companies to create a new class of therapeutic products.
    • Gene Editing Sequencing Solutions sub-sector: Includes companies that specialize in next-generation sequencing that may be used at various stages of a genome editing workflow. The companies provide sequencing methods to determine the impact of an edited sequence on the structured function of genes and analysis tools for CRISPR and gene splicing and editing.
  • Companies are initially identified by industry and sector, and are then further reviewed on the basis of operations related to CRISPR & Gene Editing technology activities.
  • The index is composed of the 40 or so largest eligible companies using float adjusted capitalization, and the largest companies make up a greater percentage of the overall portfolio.
Invest Now

It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. Strategic Investments does not sponsor, endorse, sell, promote or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index. Strategic Investments licenses its indices to third parties for the creation of investment funds or other vehicles, such as exchange-traded funds (ETFs), exchange-traded notes (ETNs), institutional asset mandates, and structured notes.

The information contained does not reflect the performance of any fund or account managed or serviced by Strategic Investments, and there is no guarantee that investors will experience the type of performance reflected above. There is no guarantee that any historical trend illustrated herein will be repeated in the future, and there is no way to predict precisely when such a trend will begin. There is no guarantee that any market forecast made in this commentary will be realized. The mention of specific securities is not a recommendation or solicitation for any person to buy, sell or hold any particular security and should not be relied upon as investment advice. The views and opinions in the preceding commentary are as of the date of publication and are subject to change without notice. This material represents an assessment of the market environment at a specific point in time, should not be relied upon as investment advice, is not intended to predict or depict performance of any investment and does not constitute a recommendation or an offer for a particular security. We consider the information in this presentation to be accurate, but we do not represent that it is complete or should be relied upon as the sole source of suitability for investment.